(Q54336627)

28 May 2018

title

First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis. (English)

1 reference

28 May 2018

Carlo Gambacorti-Passerini

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

6

1 reference

28 May 2018

author name string

Ilaria Viganò

1

1 reference

28 May 2018

Nunzio Di Giacomo

2

1 reference

28 May 2018

Sofia Bozzani

3

1 reference

28 May 2018

Laura Antolini

4

1 reference

28 May 2018

Rocco Piazza

5

1 reference

28 May 2018

publication date

31 July 2014

1 reference

28 May 2018

American Journal of Hematology

published in

1 reference

28 May 2018

volume

89

1 reference

28 May 2018

issue

10

1 reference

28 May 2018

page(s)

E184-7

1 reference

28 May 2018

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

cites work

1 reference

Structural organization of the bcr gene and its role in the Ph' translocation

21 January 2018

1 reference

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

21 January 2018

1 reference

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

21 January 2018

1 reference

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23804

1 reference

28 May 2018

PubMed ID

25041880

1 reference

28 May 2018